NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Biogen Inc. (BIIB) Stock Analysis

Biogen Inc. (BIIB) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

BIIB

$220.83

−$3.68 (−1.64%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BIIB with… →

BIIB Key Statistics

As of Sep 4, 2026
Trading
Open
$221.15
Previous Close
$224.51
Day's Range
219.82–223.82
52-Week Range
135.39–225.80
Volume
465.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.17
Valuation
Market Cap
$32.63B
P/E Ratio
39.86
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.35
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.18
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.25
EPS (ttm)Profit attributable to each share over the last twelve months.
5.54
Financials (FY)
Revenue (FY)
$9.89B+2.22%
Net Income (FY)
$1.29B−20.79%
Profit marginThe share of revenue left as profit after all costs and taxes.
8.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
147.75M
1-Year Return
+57.80%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
1.13M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BIIB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+25.48%
2025+15.09%
2024−40.91%
2023−6.55%
2022+15.42%
2021−2.02%
2020−17.48%
2019−1.39%
2018−5.54%
2017+12.34%
2016 (partial year)−9.59%

As of September 4, 2026.

BIIB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.89B$1.29B13.1%
2024$9.68B$1.63B16.9%
2023$9.84B$1.16B11.8%
2022$10.17B$3.05B29.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.89B$7.49B$2.47B$1.29B13.1%
2024$9.68B$7.37B$2.28B$1.63B16.9%
2023$9.84B$7.30B$1.85B$1.16B11.8%
2022$10.17B$7.90B$2.90B$3.05B29.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BIIB Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricBIIBDrug Manufacturers - General medianvs median
P/E39.8624.6961% above
P/S ratio3.253.134% above
Profit margin8.32%8.09%0.2 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Biogen Inc. (BIIB) is capitalised at $32.63B on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 7,500 employees.

BIIB last closed at $220.83 on September 4, 2026. That is −$3.68 (−1.64%) against the previous close. The 52-week range on file runs from $135.39 to $225.80. The latest close sits 63.11% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $9.89B. Against the prior fiscal year total of $9.68B, that is a change of +2.22%. Net income for the same year was $1.29B. That is −20.79% against the prior fiscal year. The reported profit margin is 8.32%. That is 0.2 percentage points above the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are 5.54.

Across the 4 fiscal years on file, revenue moves from $10.17B in 2022 to $9.89B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 39.86. That is 61.44% above the Drug Manufacturers - General median of 24.69. On forward earnings the ratio is 13.35. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.18. The price-to-sales ratio is 3.25. On price-to-sales that is 3.9% above the Drug Manufacturers - General median of 3.13. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +57.80%. Measured over 10 years, that is −3.45% a year compounded. Beta against the wider market is reported at 0.17. Annualized volatility over the trailing 10 years is 41.38%.

Growth & Income

The record shows no dividend for BIIB.

Across the complete calendar years on file, 2022 returned +15.42% and 2024 returned −40.91%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is +25.48%.

Peer Comparison

Biogen Inc. (BIIB) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biogen Inc. BIIB $32.63B 39.9
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Biogen Inc. trades at a P/E of 39.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Visit website →